This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) During Pregnancy

Sponsored by AbbVie

About this trial

Last updated 2 years ago

Study ID

MED-EPI-NEU-0649

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18-75 Years
18+ Years
Female
Female

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 3 years ago

What is this trial about?

Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity. The purpose of this study is to evaluate fetal, maternal, and infant outcomes through 12 months of age among women exposed to Ubrelvy during pregnancy, as well as in 2 Ubrelvy-unexposed comparison groups. Ubrelvy (ubrogepant) is an approved drug for the acute treatment of migraine in adults. Approximately 560 pregnant women with migraine exposed to Ubrelvy and 560 pregnant women with migraine without exposure to Ubrelvy will be enrolled in this study in the United States. Participants enrolled in the Ubrelvy-exposed group will receive Ubrelvy as prescribed by their physician. There may be higher treatment burden for participants in this trial compared to their standard of care.

What are the participation requirements?

Yes

Inclusion Criteria

- Within the United States.

- Qualify as a prospective enrollment, defined as currently pregnant.

- A diagnosis of migraine by the patient's health care provider (HCP).

- Provide contact information for the participant and her and her infant(s)', if applicable, HCPs.

- Authorize their HCP(s) to release maternal and infant medical information to the registry, upon request.

- Provide sufficient information to confirm eligibility for 1 of following:

- Ubrelvy-exposed women with migraine: adequate information to conclude that at least 1 dose of Ubrelvy was taken during pregnancy, including date(s) of administration.
- Unexposed women with migraine (treated or untreated): adequate information to conclude that she has never taken Ubrelvy or discontinued Ubrelvy at least 3 months prior the first day of last menstrual period (LMP).
No

Exclusion Criteria

- Documentation of exposure to any gepants (acute or preventive) other than Ubrelvy from 5 half-lives prior to the first day of LMP or at any point during pregnancy before enrollment.

- Women who are no longer pregnant (retrospective cases women for whom the pregnancy has already ended, and the outcome of pregnancy is known at the time of enrollment).

Locations

Location

Status

Recruiting